DYSLIPIDEMIA AND BENIGN BREAST DISEASES
Abstract
https://doi.org/10.31386/dmj.2022.16.2.5
Background: Benign breast disorders are the most common abnormalities found in women as far as breast disease is concerned. The study's goal was to see if there is a link between serum dyslipidemia and benign breast diseases in women.
Subjects and Methods: This is a case-control study, that involved 70 patients with benign breast diseases (cyclical mastalgia, fibrocystic breast disease and fibroadenoma) and 70 control healthy women and all of them had been selected randomly, aged (20-45 years) in a period between 1st September. 2021- 30th June. 2022. It is hospital-based study, The patients’ group was carried out at the breast clinic at Azadi teaching hospital, while healthy participants in control group had been recruited in this study from different places in Duhok city such as governmental institutions, camps and universities with matching ages.
Results: The mean age of patients and control groups was 33.5±7.6 and 33.1±6.5 respectively. Fibrocystic breast disease constitutes 40 % of patients with benign breast diseases, while 38 % of them had cyclical mastalgia and only 21% had fibroadenoma. Seventy-Eight percent of patients had a normal lipid profiles and it is also normal in 80 % of a control group (P value less than <0.8). There was a significant difference in total cholesterol and VLDL between patients and control groups (P value less than <0.004 and 0.0005 consequently). Regarding the relationship of a lipid profile to the different etiologies of benign breast diseases, all parameters were not significant between different groups except for LDL and VLDL, as it was significant when we compare fibroadenoma to fibrocystic breast diseases with the P-value of 0.0001 and 0.0002 consequently. Also, when we compare fibroadenoma and cyclical mastalgia, there was a significant difference between LDL and VLDL with P values of 0.0001 and 0.01consequently.
Conclusion: There is a clear association between benign breast diseases and some parameters of lipid profile such as total cholesterol and VLDL. We do recommend measuring lipid profiles in these groups of patients especially those with fibroadenoma
Downloads
References
1. Gerber M, Richardson S, Crastes de Paulet P, Pujol H, Crastes de Paulet A. Relationship between vitamin E and polyunsaturated fatty acids in breast cancer. Nutritional and metabolic aspects. Cancer. 1989;64:2347–53.
2. Caleffi M, Filho DD, Borghetti K. Cryoablation of benign breast tumors: evolution of technique and technology. Breast. 2004;13:397–407.
3. Namazi A, Adibi A, Haghighi M, Hashemi M. An Evaluation of Ultrasound Features of Breast Fibroadenoma. Adv Biomed Res. 2017;6:153
4. Krings G, Bean GR, Chen YY. Fibroepithelial lesions; The WHO spectrum. Semin Diagn Pathol. 2017 Sep;34(5):438-452.
5. Sandadi S, Rock DT, Orr JW Jr., Valea FA. Breast diseases: detection, management and surveillance of breast diseases. In: Lobo RA, Gershenson DM, Lentz GM, Valea FA, editors. Comprehensive gynaecology. 7th ed. Philadelphia: Elsevier; 2017. p. 294-328.
6. Meisner ALW, Fekrazad MH, Royce ME. Med Clin N Am, 2008; 92:1115-1141.
7. Andrews WC. J Reprod Med, 1990; 35 Suppl 1:87- 90.
8. Courtillot C, Plu-Bureau G, Binart N, Balleyguier C,et al. J Mammary Gland Biol Neoplasia, 2005; 10:325-335.
9. Rosai J. Rosai and Ackerman’s surgical pathology. Volume 2. 9th ed. Missouri: Mosby; 2004. p. 177- 178.
10. Khanna,S.; Singh, S.; Khanna,H.D.; et al. Evaluation of Estradiol Levels, Lipid Profile, Estrogen Receptor Status and it Correlation with Histological Variants in Benign Breast Diseases. (2012). World J. Pathol.1:10-13.
11. Vorherr H. Fibrocystic breast disease: pathophysiology, pathomorphology, clinical picture, and management. Am J Obstet Gynecol. 1986 Jan;154(1):161-79. doi: 10.1016/0002-9378(86)90421-7. PMID: 3511705.
12. D.N. Ader, J. South-Paul, T. Adera, P.A. Deuster,Cyclical mastalgia: prevalence and associated health and behavioral factors.J Psychosom Obstet Gynaecol, 22 (2) (2001), pp. 71-76.
13. J. Iddon, J.M. Dixon Mastalgia ,BMJ, 347 (2013), p. f3288.
14. Pfeifer JD, Barr RJ, Wick MR. Ectopic breast tissue and breast-like sweat Gland metaplasias: an overlapping spectrum of lesions. J Cutan Pathol. 1999;26:190–6.
15. Jellinger PS, Handelsman Y, Rosenblit PD, et al. American association of clinical endocrinologists and american college of endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocr Pract. 2017;23(Suppl 2):1-87. doi:10.4158/EP171764.APPGL
16. Prabakar MS, Prakasam N, Reshma S, Loganathan K, Palani V. A clinical study of serum lipid profile in benign breast disease in a tertiary care hospital. Int Surg J 2019;6:3162-4
17. Gonenc A, Erten D, Aslan S, Akinci M, Simsek B, Torun M. Lipid peroxidation and antioxidant status in blood and tissue of malignant breast tumor and benign breast disease. J Int Cell Biol. 2006;30:376- 80
18. Khanna AK, Tapadar JK, Khanna HD, Khanna S, Khanna A. Behavior of estrogen receptor, histological correlation and clinical outcome in patients with benign breast disorder. Eur J Surg. 2002;168:631-4.
19. Shaymaa,Mhammed, Alkhalifa, Jenan. Study the role of lipid profile in the incidence of benign breast tumors in the women year. International Journal of Scientific & Engineering Research, Volume 6, Issue 11, November-2015. 356 ISSN 2229-5518.
20. Susil R, Bhupati Das, Sushanta Das; et al. Study of the lipid profile in patients having benign breast disease. Journal of evidence based medicine and healthcare. 2015; 2(14):2218-2227.
